NDASUBLINGUALFILM
Approved
May 2020
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
4/8 — Partial
KYNMOBI (apomorphine hydrochloride) by Sumitomo Dainippon Pharma is non-ergoline dopamine agonist with high in vitro binding affinity for the dopamine d4 receptor, and moderate affinity for the dopamine d2, d3, and d5, and adrenergic α1d, α2b, α2c receptors. First approved in 2020.
Drug data last refreshed 7h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
KYNMOBI is an apomorphine hydrochloride sublingual film approved in 2020 for Parkinson's disease, a non-ergoline dopamine agonist that stimulates post-synaptic D2-type receptors to manage motor symptoms. It represents a novel delivery mechanism (sublingual film) for rapid dopamine agonism in an established therapeutic class. The drug targets patients experiencing motor fluctuations during peak Parkinson's disease management phases.
$0.002BPart D
Peak9.8 years to LOEProduct is at peak market penetration with modest Medicare spending (~$2M in 2023), suggesting a small but established patient base and specialized sales infrastructure.
Mechanism of Action
non-ergoline dopamine agonist with high in vitro binding affinity for the dopamine D4 receptor, and moderate affinity for the dopamine D2, D3, and D5, and adrenergic α1D, α2B, α2C receptors. The precise mechanism of action of ONAPGO as a treatment for Parkinson's disease is unknown, although it is…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
KYNMOBI offers a niche career opportunity in specialty neurology focused on a small but growing Parkinson's disease population; roles emphasize direct physician engagement, specialty pharmacy partnerships, and patient support rather than broad primary care promotion. Career progression depends on market share gains and regional expansion within movement disorder practices.
Brand Manager
Worked on KYNMOBI at Sumitomo Dainippon Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.